These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 1910070

  • 1. Safety, pharmacokinetics, and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and nonseptic patients.
    Saravolatz LD, Markowitz N, Collins MS, Bogdanoff D, Pennington JE.
    J Infect Dis; 1991 Oct; 164(4):803-6. PubMed ID: 1910070
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of an IgM human monoclonal antibody against Pseudomonas aeruginosa in nonseptic patients.
    Meng YG, Wong T, Saravolatz LD, Pennington JE.
    J Infect Dis; 1993 Mar; 167(3):784-5. PubMed ID: 8440953
    [No Abstract] [Full Text] [Related]

  • 3. Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa.
    Collins MS, Ladehoff DK, Mehton NS, Noonan JS.
    FEMS Microbiol Immunol; 1990 Dec; 2(5-6):263-8. PubMed ID: 2127368
    [Abstract] [Full Text] [Related]

  • 4. Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia.
    Pennington JE, Small GJ, Lostrom ME, Pier GB.
    Infect Immun; 1986 Oct; 54(1):239-44. PubMed ID: 3093385
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacodynamic and protective properties of a murine lipopolysaccharide-specific monoclonal antibody in experimental Pseudomonas aeruginosa pneumonia in mice.
    Oishi K, Sonoda F, Miwa H, Tanaka H, Watanabe K, Matsumoto K, Pollack M.
    Microbiol Immunol; 1991 Oct; 35(12):1131-41. PubMed ID: 1808464
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics, tolerability, and preliminary efficacy of human anti-Pseudomonas aeruginosa monoclonal antibodies in pneumonia and burn infection patients.
    Harrison FJ, Rohm D, Kohzuki T, Noguchi H.
    Hybridoma; 1997 Oct; 16(5):413-20. PubMed ID: 9388024
    [Abstract] [Full Text] [Related]

  • 9. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.
    Hemachandra S, Kamboj K, Copfer J, Pier G, Green LL, Schreiber JR.
    Infect Immun; 2001 Apr; 69(4):2223-9. PubMed ID: 11254577
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia.
    Oishi K, Sonoda F, Iwagaki A, Ponglertnapagorn P, Watanabe K, Nagatake T, Siadak A, Pollack M, Matsumoto K.
    Antimicrob Agents Chemother; 1993 Feb; 37(2):164-70. PubMed ID: 8383936
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Immunotherapeutic potential of monoclonal antibodies against Pseudomonas aeruginosa protein F.
    Hancock RE, Mutharia LM, Mouat EC.
    Eur J Clin Microbiol; 1985 Apr; 4(2):224-7. PubMed ID: 2408887
    [Abstract] [Full Text] [Related]

  • 14. Treatment of experimental Pseudomonas aeruginosa pneumonia with a human IgM monoclonal antibody.
    Hector RF, Collins MS, Pennington JE.
    J Infect Dis; 1989 Sep; 160(3):483-9. PubMed ID: 2760499
    [Abstract] [Full Text] [Related]

  • 15. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa.
    DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK.
    Sci Transl Med; 2014 Nov 12; 6(262):262ra155. PubMed ID: 25391481
    [Abstract] [Full Text] [Related]

  • 16. [Use of pseudomonas immunoglobulin. Indications and results].
    Werdan K, Melnitzki S, Pilz G, Reuschel-Janetschek E.
    Anasth Intensivther Notfallmed; 1989 Jun 12; 24(3):153-61. PubMed ID: 2504071
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults.
    Ali SO, Yu XQ, Robbie GJ, Wu Y, Shoemaker K, Yu L, DiGiandomenico A, Keller AE, Anude C, Hernandez-Illas M, Bellamy T, Falloon J, Dubovsky F, Jafri HS.
    Clin Microbiol Infect; 2019 May 12; 25(5):629.e1-629.e6. PubMed ID: 30107283
    [Abstract] [Full Text] [Related]

  • 19. Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.
    Thaden JT, Keller AE, Shire NJ, Camara MM, Otterson L, Huband M, Guenther CM, Zhao W, Warrener P, Stover CK, Fowler VG, DiGiandomenico A.
    J Infect Dis; 2016 Feb 15; 213(4):640-8. PubMed ID: 26333940
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa.
    Shime N, Sawa T, Fujimoto J, Faure K, Allmond LR, Karaca T, Swanson BL, Spack EG, Wiener-Kronish JP.
    J Immunol; 2001 Nov 15; 167(10):5880-6. PubMed ID: 11698464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.